Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment

被引:50
|
作者
Zeerleder, Sacha [1 ,2 ,3 ]
Levi, Marcel [4 ]
机构
[1] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands
[2] AMC, Landsteiner Lab, Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1012 WX Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1012 WX Amsterdam, Netherlands
关键词
Acquired angioedema; bradykinin; bradykinin-receptor; 2; C1-inhibitor; factor VII-activating protease; factor XII; hereditary angioedema; high-molecular kininogen; kallikrein; low-molecular kininogen; C1 INHIBITOR CONCENTRATE; NONPEPTIDE B-2 ANTAGONIST; KALLIKREIN-KININ SYSTEM; FACTOR-XII; C1-ESTERASE INHIBITOR; ESTERASE INHIBITOR; TRANEXAMIC ACID; MISSENSE MUTATIONS; CLINICAL-FEATURES; SERINE-PROTEASE;
D O I
10.3109/07853890.2016.1162909
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Uncontrolled generation of bradykinin (BK) due to insufficient levels of protease inhibitors controlling contact phase (CP) activation, increased activity of CP proteins, and/or inadequate degradation of BK into inactive peptides increases vascular permeability via BK-receptor 2 (BKR2) and results in subcutaneous and submucosal edema formation. Hereditary and acquired angioedema due to C1-inhibitor deficiency (C1-INH-HAE and -AAE) are diseases characterized by serious and potentially fatal attacks of subcutaneous and submucosal edemas of upper airways, facial structures, abdomen, and extremities, due to inadequate control of BK generation. A decreased activity of C1-inhibitor is the hallmark of C1-INH-HAE (types 1 and 2) due to a mutation in the C1-inhibitor gene, whereas the deficiency in C1-inhibitor in C1-INH-AAE is the result of autoimmune phenomena. In HAE with normal C1-inhibitor, a significant percentage of patients have an increased activity of factor XIIa due to a FXII mutation (FXII-HAE). Treatment of C1-inhibitor-dependent angioedema focuses on restoring control of BK generation by inhibition of CP proteases by correcting the balance between CP inhibitors and BK breakdown or by inhibition of BK-mediated effects at the BKR2 on endothelial cells. This review will address the pathophysiology, clinical picture, diagnosis and available treatment in C1-inhibitor-dependent angioedema focusing on BK-release and its regulation.Key MessagesInadequate control of bradykinin formation results in the formation of characteristic subcutaneous and submucosal edemas of the skin, upper airways, facial structures, abdomen and extremities as seen in hereditary and acquired C1-inhibitor-dependent angioedema.Diagnosis of hereditary and acquired C1-inhibitor-dependent angioedema may be troublesome as illustrated by the fact that there is a significant delay in diagnosis; a certain grade of suspicion is therefore crucial for quick diagnosis.Submucosal edema formation in hereditary and acquired C1-inhibitor-dependent angioedema is potentially life threatening and can occur at any age.To date effective therapies for acute and prophylactic treatment are available.
引用
收藏
页码:256 / 267
页数:12
相关论文
共 50 条
  • [21] Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema
    Anderson, John
    Maina, Njeri
    CLINICAL AND TRANSLATIONAL ALLERGY, 2022, 12 (01)
  • [22] Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate
    Bork, Konrad
    Staubach-Renz, Petra
    Hardt, Jochen
    ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (1)
  • [23] Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema
    Ania L. Manson
    John Dempster
    Sofia Grigoriadou
    Matthew S. Buckland
    Hilary J. Longhurst
    European Journal of Dermatology, 2014, 24 : 28 - 34
  • [24] Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor
    Larrauri, Blas
    Hester, C. Garren
    Jiang, Haixiang
    Miletic, Vojislav D.
    Malbran, Alejandro
    Bork, Konrad
    Kaplan, Allen
    Frank, Michael
    MOLECULAR IMMUNOLOGY, 2021, 136 : 150 - 160
  • [25] C1 inhibitor deficiency: Hereditary and acquired forms
    Kaplan, AP
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY, 2001, 11 (04) : 211 - 219
  • [26] A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema
    Zuraw, Bruce L.
    Bernstein, Jonathan A.
    Lang, David M.
    Craig, Timothy
    Dreyfus, David
    Hsieh, Fred
    Khan, David
    Sheikh, Javed
    Weldon, David
    Bernstein, David I.
    Blessing-Moore, Joann
    Cox, Linda
    Nicklas, Richard A.
    Oppenheimer, John
    Portnoy, Jay M.
    Randolph, Christopher R.
    Schuller, Diane E.
    Spector, Sheldon L.
    Tilles, Stephen A.
    Wallace, Dana
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (06) : 1491 - +
  • [27] Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor
    Konrad Bork
    Allergy, Asthma & Clinical Immunology, 6 (1)
  • [28] C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema
    Madsen, Daniel Elenius
    Sidelmann, Johannes Jakobsen
    Biltoft, Daniel
    Gram, Jorgen
    Hansen, Soren
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2015, 1850 (06): : 1336 - 1342
  • [29] Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema
    Deroux, A.
    Boccon-Gibod, I.
    Fain, O.
    Pralong, P.
    Ollivier, Y.
    Pagnier, A.
    Djenouhat, K.
    Du-Thanh, A.
    Gompel, A.
    Faisant, C.
    Launay, D.
    Bouillet, L.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2016, 185 (03) : 332 - 337
  • [30] Gene Mutations Linked to Hereditary Angioedema in Solitary Angioedema Patients With Normal C1 Inhibitor
    Bork, Konrad
    Wulff, Karin
    Witzke, Gunther
    Staubach, Petra
    Hardt, Jochen
    Meinke, Peter
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (08) : 2441 - 2449